Ludwig Nicole, Keller Andreas, Comtesse Nicole, Rheinheimer Stefanie, Pallasch Christian, Fischer Ulrike, Fassbender Klaus, Steudel Wolf Ingo, Lenhof Hans-Peter, Meese Eckart
Department of Human Genetics, Medical School, Saarland University, Homburg/Saar, Germany.
Clin Cancer Res. 2008 Aug 1;14(15):4767-74. doi: 10.1158/1078-0432.CCR-07-4715.
Recent studies impressively showed the diagnostic potential of seroreactivity patterns for different tumor types, offering the prospect for low-cost screening of numerous tumor types simultaneously. One of the major challenges toward this goal is to prove that seroreactivity profiles do not only allow for identifying a tumor but also allow for distinguishing tumors from other pathologies of the same organ.
We chose glioma as a model system and tested 325 sera (88 glioma, 95 intracranial tumors, 60 other brain pathologies, and 82 healthy controls) for seroreactivity on a panel of 35 antigens.
We were able to discriminate between glioma and all other sera with cross-validated specificity of 86.1%, sensitivity of 85.2%, and accuracy of 85.8%. We obtained comparably good results for the separation of glioma versus nontumor brain pathologies and glioma versus other intracranial tumors.
Our study provides first evidence that seroreactivity patterns allow for an accurate discrimination between a tumor and pathologies of the same organ even between different tumor types of the same organ.
近期研究令人印象深刻地显示了不同肿瘤类型血清反应模式的诊断潜力，为同时低成本筛查多种肿瘤类型提供了前景。实现这一目标的主要挑战之一是证明血清反应谱不仅能够识别肿瘤，还能够将肿瘤与同一器官的其他病理状况区分开来。
我们选择神经胶质瘤作为模型系统，在一组35种抗原上检测了325份血清（88份神经胶质瘤血清、95份颅内肿瘤血清、60份其他脑部病理血清和82份健康对照血清）的血清反应性。
我们能够区分神经胶质瘤与所有其他血清，交叉验证的特异性为86.1%，敏感性为85.2%，准确性为85.8%。在区分神经胶质瘤与非肿瘤性脑部病理状况以及神经胶质瘤与其他颅内肿瘤方面，我们也取得了相当不错的结果。
我们的研究首次证明，血清反应模式能够准确区分肿瘤与同一器官的病理状况，甚至是同一器官的不同肿瘤类型之间。
